论文部分内容阅读
目的探讨紫杉醇联合顺铂同步放疗治疗中晚期食管癌的疗效和不良反应。方法将84例中晚期食管癌患者随机分为单放组(单纯放疗治疗)和放化组(紫杉醇联合顺铂同步放疗治疗),每组各42例,观察并比较两组临床疗效和不良反应。结果放化组近期疗效,1、2、3年生存率均高于单放组(P<0.05)。放化组的放射性食管炎、恶心、白细胞下降和黏膜炎的发生率高于单放组(P<0.05),但均为轻度(Ⅰ～Ⅱ度),经对症处理均缓解。结论紫杉醇联合顺铂同步放疗治疗中晚期食管癌能提高近期疗效、总生存率,但近期毒副反应仍高于单放组。
Objective To investigate the efficacy and side effects of concurrent paclitaxel and cisplatin in the treatment of advanced esophageal cancer. Methods Eighty-four patients with advanced esophageal cancer were randomly divided into radiotherapy group (radiotherapy alone) and radiotherapy group (paclitaxel plus cisplatin concurrent radiotherapy), 42 cases in each group. The clinical efficacy and adverse reactions of the two groups were observed and compared . Results The curative effect of radiotherapy and chemotherapy group was higher than that of radiotherapy alone group (P <0.05). The incidence of radiation esophagitis, nausea, leukopenia and mucositis in radiotherapy group was higher than that in radiotherapy group (P <0.05), but both were mild (Ⅰ ~ Ⅱ degree) and were relieved symptomatically. Conclusions Paclitaxel plus cisplatin combined with concurrent radiotherapy in the treatment of advanced esophageal cancer can improve the short-term efficacy and overall survival rate, but the recent toxicity is still higher than the single radiotherapy group.